Cardiovascular Genomic Diagnostics Market

Market Overview

Heart related disorders are mostly inherited from parents to their children. Cardiovascular genomic diagnostics testing helps in detecting these inherited diseases such as cardiac channelopathies and congenital heart diseases. Besides cardiovascular genomic diagnostics can also be helpful for family members who have risks of developing heart problems.

These genetic disorders affect by impairing development of blood vessels which leads to onset of heart diseases. Therefore, cardiovascular genomic diagnostics help in identification of genetic deformities for saving lives.

The technology used for cardiovascular genomic diagnostics testing are NGS (Next generation Sequencing) and Multiplex Ligation-Dependent Probe Amplification (MLPA). These technologies in cardiovascular genomic diagnostics tests read the genetic content of the deceased DNA to identify the changes in its sequence

Market Segmentation

On the basis of test type	Predictive Testing Genetic Susceptibility Test Predictive Diagnostics Population Screening Carrier Screening Prenatal Testing Genotyping
On the basis of disease indication	Congenital Heart Disease Cardiac Channelopathies Familial Hyper-Cholestrolaemia Cardiomyopathies Others
On the basis of technological platform	Generation Sequencing (NGS) Multiplex Ligation-Dependent Probe Amplification (MLPA)
On the basis of end users	Hospital Laboratories’ Diagnostic Centers Contract Research Organizations (CROs) Others

Regional Outlook

Geographically, North America is anticipated to be the leading market in the global cardiovascular genomic diagnostics market owing to the increasing number of cardiac diseases. Moreover, the regional market will also rise due to the technological advancement as well as stringent patient care and safety in the region.

The cardiovascular genomic diagnostics markets in the South and East Asia are also anticipated to grow at a significant CAGR due to product expansion offerings by the major global players. In addition, cardiovascular genomic diagnostics is poised to improve the health of population globally by decreasing rate of heart attack and congenital heart diseases. Europe is expected to have the second largest share in the global cardiovascular genomic diagnostics market throughout the forecast period

Key Players

Some of the Key manufacturers operating in the global cardiovascular genomic diagnostics market include Gnome Diagnostics, Color Genomics, Inc., Creative Diagnostics Thermo Fisher Scientific, Illumina, Inc., Admera Health, Blueprint Genetics Oy., Merck KGaA, MP Biomedicals, LLC., Helix OpCo LLC, CENTOGENE AG, and Oasis Diagnostics Corporation.

These players are adopting sophisticated techniques in the development of cardiovascular genomic diagnostics which will help them for expansion of their product offerings, strengthen geographical presence, and gain strong market share.

The report covers exhaustive analysis on:

• Global Cardiovascular Genomic Diagnostics segments
• Global Cardiovascular Genomic Diagnostics dynamics
• Historical actual market size, 2013 - 2017
• Global Cardiovascular Genomic Diagnostics size & forecast 2018 to 2026
• Global Cardiovascular Genomic Diagnostics current trends/issues/challenges
• Competition & companies involved
• Global Cardiovascular Genomic Diagnostics drivers and restraints

Regional analysis includes:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

For report customisation and delivery information contact our sales representative.